Fabio Piscaglia

49.3k total citations · 6 hit papers
368 papers, 20.9k citations indexed

About

Fabio Piscaglia is a scholar working on Hepatology, Epidemiology and Surgery. According to data from OpenAlex, Fabio Piscaglia has authored 368 papers receiving a total of 20.9k indexed citations (citations by other indexed papers that have themselves been cited), including 248 papers in Hepatology, 171 papers in Epidemiology and 90 papers in Surgery. Recurrent topics in Fabio Piscaglia's work include Hepatocellular Carcinoma Treatment and Prognosis (180 papers), Liver Disease Diagnosis and Treatment (161 papers) and Liver Disease and Transplantation (105 papers). Fabio Piscaglia is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (180 papers), Liver Disease Diagnosis and Treatment (161 papers) and Liver Disease and Transplantation (105 papers). Fabio Piscaglia collaborates with scholars based in Italy, Germany and United Kingdom. Fabio Piscaglia's co-authors include Vincenzo Mazzaferro, Luigi Bolondi, Jean‐Luc Raoul, Peter R. Galle, Alejandro Forner, Josep M. Llovet, Peter Schirmacher, Valérie Vilgrain, Rita Golfieri and Antonio Daniele Pinna and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Fabio Piscaglia

349 papers receiving 20.6k citations

Hit Papers

EASL Clinical Practice Guidelin... 2006 2026 2012 2019 2018 2017 2006 2013 2015 2.0k 4.0k 6.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
    2018 6.9k citations Fabio Piscaglia et al. profile →
  2. EFSUMB Guidelines and Recommendations on the Clinical Use of Liver Ultrasound Elastography, Update 2017 (Long Version)
    2017 742 citations Annalisa Berzigotti, Fabio Piscaglia et al. profile →
  3. The safety of Sonovue® in abdominal applications: Retrospective analysis of 23188 investigations
    2006 550 citations Fabio Piscaglia, Luigi Bolondi profile →
  4. Heterogeneity of Patients with Intermediate (BCLC B) Hepatocellular Carcinoma: Proposal for a Subclassification to Facilitate Treatment Decisions
    2013 492 citations Fabio Piscaglia, Luigi Bolondi et al. profile →
  5. Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study
    2015 427 citations Fabio Piscaglia, Anna Pecorelli et al. Hepatology profile →
  6. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: Available evidence and expert opinion on the use of transarterial chemoembolization
    2010 426 citations Fabio Piscaglia, Luigi Bolondi et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Fabio Piscaglia Italy 62 15.1k 10.7k 4.9k 2.8k 2.7k 368 20.9k
Laura Kulik United States 61 15.9k 1.0× 8.4k 0.8× 5.7k 1.2× 2.7k 1.0× 3.6k 1.3× 149 20.1k
Luigi Bolondi Italy 66 12.4k 0.8× 8.4k 0.8× 4.1k 0.8× 1.5k 0.5× 2.2k 0.8× 278 18.4k
Alejandro Forner Spain 35 17.4k 1.1× 10.1k 1.0× 4.9k 1.0× 2.3k 0.8× 3.6k 1.4× 120 25.1k
Valérie Vilgrain France 79 16.2k 1.1× 12.4k 1.2× 10.1k 2.1× 4.7k 1.7× 4.4k 1.7× 538 28.2k
Morris Sherman Canada 58 24.1k 1.6× 17.2k 1.6× 5.3k 1.1× 2.5k 0.9× 3.2k 1.2× 203 31.8k
Riccardo Lencioni Italy 69 21.6k 1.4× 11.2k 1.0× 5.6k 1.1× 3.6k 1.3× 5.6k 2.1× 290 30.0k
Bruno Sangro Spain 77 16.2k 1.1× 8.4k 0.8× 4.8k 1.0× 1.8k 0.6× 4.2k 1.6× 416 26.0k
Julie K. Heimbach United States 59 12.4k 0.8× 8.3k 0.8× 8.5k 1.7× 1.2k 0.4× 3.4k 1.3× 230 19.0k
Kwang‐Hyub Han South Korea 72 19.0k 1.3× 16.1k 1.5× 3.5k 0.7× 1.2k 0.4× 1.9k 0.7× 623 24.3k
Kiyoshi Hasegawa Japan 60 9.9k 0.7× 5.3k 0.5× 6.2k 1.3× 921 0.3× 2.9k 1.1× 550 15.9k

Countries citing papers authored by Fabio Piscaglia

Since Specialization
Citations

This map shows the geographic impact of Fabio Piscaglia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fabio Piscaglia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fabio Piscaglia more than expected).

Fields of papers citing papers by Fabio Piscaglia

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fabio Piscaglia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fabio Piscaglia. The network helps show where Fabio Piscaglia may publish in the future.

Co-authorship network of co-authors of Fabio Piscaglia

This figure shows the co-authorship network connecting the top 25 collaborators of Fabio Piscaglia. A scholar is included among the top collaborators of Fabio Piscaglia based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fabio Piscaglia. Fabio Piscaglia is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bassi, Cristian, Francesco Tovoli, Francesca Fornari, et al.. (2025). Early CTLA4 increase in CD45+ blood cells: an emerging biomarker of atezolizumab–bevacizumab resistance and worse survival in advanced hepatocarcinoma. ESMO Open. 10(3). 104289–104289. 2 indexed citations
2.
Ielasi, Luca, Bernardo Stefanini, Fabio Conti, et al.. (2024). Comparative Analysis of Subclassification Systems in Patients with Intermediate-Stage Hepatocellular Carcinoma (Barcelona Clinic Liver Classification B) Receiving Systemic Therapy. Current Oncology. 31(1). 547–557. 2 indexed citations
3.
Lupșor‐Platon, Monica, Laura Turco, S. Ferri, et al.. (2024). Diagnostic accuracy of 2D-SWE ultrasound for liver fibrosis assessment in MASLD: A multilevel random effects model meta-analysis. Hepatology. 82(2). 454–469. 4 indexed citations
4.
Boccatonda, Andrea, Antonio Corvino, Giulio Cocco, et al.. (2024). Ultrasound-Assisted and Ultrasound-Guided Thoracentesis: An Educational Review. Diagnostics. 14(11). 1124–1124. 2 indexed citations
5.
Boccatonda, Andrea, Damiano D’Ardes, Gianfranco Lessiani, et al.. (2024). Platelet, Antiplatelet Therapy and Masld: A Narrative Review. Preprints.org. 1 indexed citations
6.
Lyshchik, Andrej, Corinne E. Wessner, John R. Eisenbrey, et al.. (2023). Contrast-enhanced ultrasound liver imaging reporting and data system: clinical validation in a prospective multinational study in North America and Europe. Hepatology. 79(2). 380–391. 14 indexed citations
7.
Renzulli, Matteo, Nicolò Brandi, Stefano Brocchi, et al.. (2023). Association between anatomic variations of extrahepatic and intrahepatic bile ducts: Do look up!. Journal of Anatomy. 242(4). 683–694. 8 indexed citations
8.
Terzi, Eleonora, Massimo Iavarone, Simona Leoni, et al.. (2022). Prognosis of Single Early-Stage Hepatocellular Carcinoma (HCC) with CEUS Inconclusive Imaging (LI-RADS LR-3 and LR-4) Is No Better than Typical HCC (LR-5). Cancers. 14(2). 336–336. 11 indexed citations
9.
Granito, Alessandro, A. Forgione, Sara Marinelli, et al.. (2021). Experience with regorafenib in the treatment of hepatocellular carcinoma. Therapeutic Advances in Gastroenterology. 14. 1088199935–1088199935. 100 indexed citations
10.
11.
Muratori, L., et al.. (2021). Efficacy of a short course of lung ultrasound for primary care physicians in the assessment of COVID-19-positive patients. Family Practice. 39(4). 656–661. 3 indexed citations
12.
Granito, Alessandro, Sara Marinelli, A. Forgione, et al.. (2021). Regorafenib Combined with Other Systemic Therapies: Exploring Promising Therapeutic Combinations in HCC. Journal of Hepatocellular Carcinoma. Volume 8. 477–492. 26 indexed citations
13.
Gramantieri, Laura, Daniela Pollutri, Martina Gagliardi, et al.. (2020). MiR-30e-3p Influences Tumor Phenotype through MDM2 / TP53 Axis and Predicts Sorafenib Resistance in Hepatocellular Carcinoma. Cancer Research. 80(8). 1720–1734. 50 indexed citations
14.
Renzulli, Matteo, Stefano Brocchi, Anna Maria Ierardi, et al.. (2020). Imaging-based diagnosis of benign lesions and pseudolesions in the cirrhotic liver. Magnetic Resonance Imaging. 75. 9–20. 11 indexed citations
15.
Ravaioli, Matteo, Federica Odaldi, Alessandro Cucchetti, et al.. (2019). Long term results of down-staging and liver transplantation for patients with hepatocellular carcinoma beyond the conventional criteria. Scientific Reports. 9(1). 3781–3781. 17 indexed citations
16.
17.
Pettinari, Irene, Ranka Vukotic, Horia Ştefănescu, et al.. (2018). Clinical Impact and Safety of Anticoagulants for Portal Vein Thrombosis in Cirrhosis. The American Journal of Gastroenterology. 114(2). 258–266. 80 indexed citations
18.
Bernuzzi, Francesca, Francesco Marabita, Ana Lleò, et al.. (2016). Serum microRNAs as novel biomarkers for primary sclerosing cholangitis and cholangiocarcinoma. Clinical & Experimental Immunology. 185(1). 61–71. 70 indexed citations
19.
Piscaglia, Fabio, Valeria Camaggi, Matteo Ravaioli, et al.. (2007). A New Priority Policy for Patients with Hepatocellular Carcinoma Awaiting Liver Transplantation Within the Model for End-Stage Liver Disease System. Liver Transplantation. 13(6). 857–866. 35 indexed citations
20.
Bolondi, Luigi, Stefano Gaiani, Natascia Celli, et al.. (2005). Characterization of Small Nodules in Cirrhosis by Assessment of Vascularity: The Problem of Hypovascular Hepatocellular Carcinoma *. Hepatology. 42(1). 27–34. 333 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Laura Kulik Breakdown of academic impact, for papers by Luigi Bolondi Breakdown of academic impact, for papers by Alejandro Forner Breakdown of academic impact, for papers by Valérie Vilgrain Breakdown of academic impact, for papers by Morris Sherman Breakdown of academic impact, for papers by Riccardo Lencioni Breakdown of academic impact, for papers by Bruno Sangro Breakdown of academic impact, for papers by Julie K. Heimbach Breakdown of academic impact, for papers by Kwang‐Hyub Han Breakdown of academic impact, for papers by Kiyoshi Hasegawa
Rankless by CCL
2026